Coinfection
15
0
0
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.7%
1 terminated out of 15 trials
88.9%
+2.4% vs benchmark
20%
3 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection
Analysis of Single Respiratory Viral Infections Versus Co-infections: Prevalence and ICU Needs in Hospitalized Adults
Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet
Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents
Virus Interactions in the Respiratory Tract; a Cohort Study With Children
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children
Prospective Cohort of HIV/HBV-coinfected Patients in Europe
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection
Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana
Effects of Viral and Bacterial Co-infections in Otherwise Healthy Children Hospitalized in Pediatric Department